AMD eye drop enters Phase II

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

ATG3 is a proprietary ophthalmic formulation of mecamylamine, an antagonist of the nicotinic acetylcholine receptor pathway that mediates angiogenesis.

The Phase II study will enrol 330 subjects to be randomized into one of three treatment groups: two different doses of ATG3 administered twice daily, or placebo. All subjects will be monitored over a 48-week period to assess the drug's safety, tolerability and efficacy.

During the Phase I trial, the drug demonstrated good ocular tolerability in 80 subjects and confirmed that systemic exposure following eyedrop administration is minimal, with no systemic side effects. Furthermore, studies in animal models have shown good penetration of the formulation to the retina and choroids, as well as a reduction of new blood vessel growth in the eye.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.